According to the announcement of Xiangyu Medical, the cumulative deviation value of the company's stock price increase reached 30% on December 31, 2025, January 5, and January 6, 2026, which is an abnormal fluctuation. After self-inspection, the company, controlling shareholders, and actual controllers were not required to disclose material information that had not been disclosed. The company focuses on non-intrusive brain-computer interface technology. As of the end of 2025, related products have not been sold on a large scale and account for a small share of revenue. In the first three quarters of 2025, the company's revenue was 537,0298 million yuan, up 6% year on year; net profit was 43.9815 million yuan, down 40.09% year on year. The company reminds investors to be aware of the risk of stock price fluctuations.

According to the announcement of Xiangyu Medical, the cumulative deviation value of the company's stock price increase reached 30% on December 31, 2025, January 5, and January 6, 2026, which is an abnormal fluctuation. After self-inspection, the company, controlling shareholders, and actual controllers were not required to disclose material information that had not been disclosed. The company focuses on non-intrusive brain-computer interface technology. As of the end of 2025, related products have not been sold on a large scale and account for a small share of revenue. In the first three quarters of 2025, the company's revenue was 537,0298 million yuan, up 6% year on year; net profit was 43.9815 million yuan, down 40.09% year on year. The company reminds investors to be aware of the risk of stock price fluctuations.